Abstract
Background: OBELICS was a randomized phase 3 trial evaluating the optimization of bevacizumab schedule in the treatment of advanced colorectal cancer, not suitable for curative surgery. The sequential schedule of bevacizumab, given 3 days before chemotherapy, did not improve response rate nor progression-free survival (PFS), while prolonged median overall survival (OS) of about 6 months
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
